BMJ Open Therapeutic effects of exercise interventions for patients with chronic kidney disease: an umbrella review of systematic reviews and meta-analyses

Fan Zhang,¹ Yan Bai,² Xing Zhao,² Liuyan Huang,¹ Weiqiong Wang,³ Wenqin Zhou,⁴ Huachun Zhang ¹

ABSTRACT

Objective To conduct an overview of meta-analyses evaluating the impact of exercise interventions on improving health outcomes in patients with chronic kidney disease (CKD).

Design An umbrella review of systematic review and meta-analyses of intervention trials was performed. **Data sources** PubMed, Web of Science, Embase and the Cochrane Database of Systematic Reviews were searched from inception to 9 March 2021 for relevant articles. **Eligibility criteria for selecting studies** Eligible metaanalyses compared the effects of usual care with and without exercise in patients with CKD. Health outcomes included those related to cardiovascular risk factors, physical fitness, dialysis-related symptoms, dialysis adequacy and health-related quality of life. Systematic reviews and meta-analyses that included fewer than 3 RCTs or fewer than 100 participants were excluded from the analysis.

Results A total of 31 eligible systematic reviews and meta-analyses were included that assessed 120 outcomes. For physical fitness, there was a moderate effect size for cardiorespiratory fitness, muscle strength and body composition and small effect size for muscle endurance. The effect sizes for cardiovascular risk factors, dialysis-related symptoms and health-related quality of life outcomes were small. According to the Grading of Recommendations Assessment, Development and Evaluation framework, most outcomes were low or very low quality.

Conclusion Exercise appears to be a safe way to affect concomitant cardiovascular risk factors, such as blood pressure, improve physical fitness and health-related quality of life and reduce dialysis-related symptoms in patients with CKD.

PROSPERO registration number CRD42020223591.

INTRODUCTION

Chronic kidney disease (CKD) is a longterm condition characterised by the gradual loss of renal function over time.¹ In the past 30 years, the mortality attributed to CKD increased by 41.5%, a percentage rate that exceeds several cancers and cardiovascular diseases.² With the increasing incidence

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ A strength of this study is to comprehensively summarise the systematic review and meta-analysis of exercise interventions on the spectrum of chronic kidney disease.
- \Rightarrow Methodological quality of the included reviews was assessed using standardised measures.
- ⇒ The limitation of this overview is that language bias may exist in this review because the search strategy was limited to English.
- ⇒ Another limitation was that most studies were based on haemodialysis-dependent chronic kidney disease.

of hypertension, diabetes and obesity, this number will continue to rise.^{3 4} Patients with CKD experience a high symptom burden with progressively impaired physical performance, leading to decreased kidney function, lower health-related quality of life (HRQOL), increased risk of cardiovascular events and increased all-cause mortality.^{5 6}

With an increasing number of patients with CKD living longer, the effectiveness and accessibility of their health services have never been more critical. Renal rehabilitation is a multifaceted intervention programme. Rehabilitation consists of exercise interventions, diet control, fluid management and psychological support to alleviate physical/mental deficiencies caused by kidney disease and renal replacement therapy to improve disease prognosis and prolong life expectancy.⁷ Since exercise is the core of renal rehabilitation, there is an increasing number of systematic reviews and meta-analyses investigating the influence of exercise on health outcomes in patients with CKD.⁸

Data from large cohort studies show that mortality risk was lower for regular (equal to or more than once/week) versus non-regular (less than once/week) exercisers (adjusted

To cite: Zhang F, Bai Y, Zhao X, *et al.* Therapeutic effects of exercise interventions for patients with chronic kidney disease: an umbrella review of systematic reviews and meta-analyses. *BMJ Open* 2022;**12**:e054887. doi:10.1136/ bmjopen-2021-054887

Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (http://dx.doi.org/10.1136/ bmjopen-2021-054887).

Received 12 July 2021 Accepted 11 August 2022



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Department of Nephrology, LongHua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China ²Department of Cardiology, LongHua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China ³Blood Purification Centre. Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China ⁴Department of Nursing, LongHua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China

Correspondence to Dr Huachun Zhang; Ihhlky@163.com HR=0.73, 95% CI: 0.69 to 0.78), and mortality risk tended to decrease as exercise frequency increased (HR for participants who exercised once/week=0.82, 95% CI: 0.73 to 0.91; HR for those who exercised 6-7 times/week=0.69, 95% CI: 0.63 to 0.76) and patients who exercised daily had lower mortality risk (HR=0.84, 95% CI: 0.74 to 0.96) than patients exercising once/week.9 Based on data from 41 randomised controlled trials (RCT), Heiwe et al reported practical improvements in aerobic capacity, muscular function and walking capacity in patients with CKD after exercise,¹⁰ indicators that are the core of frailty.¹¹ In other words, exercise is an essential non-pharmacological strategy to improve frailty symptoms in patients with CKD, the latter being a significant cause of sedentary behaviour in such population.¹² Because of this, some researchers and guidelines recommend that healthcare providers prescribe exercise for patients with CKD.^{13–16} However, the results of meta-analyses of exercise in patients with CKD are inconsistent.

This umbrella review aims to assess the therapeutic effects of exercise on cardiovascular risk factors, physical fitness, dialysis-related symptoms, dialysis adequacy and HRQOL in patients with CKD, summarised in systematic reviews and meta-analyses.

METHODS AND ANALYSIS

This umbrella review follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.¹⁷ The review was prospectively registered (PROSPERO: CRD42020223591), and the protocol for this review was published.¹⁸

Patient and public involvement

Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Literature search

A comprehensive search strategy was performed to identify systematic reviews and meta-analyses of patients with CKD that compared usual care procedures with and without exercise interventions. PubMed, Embase, the Cochrane Database of Systematic Reviews and the Web of Science were searched for systematic reviews and meta-analyses from inception to 9 March 2021. The detailed search strategy is summarised in online supplemental table S1. The references of existing systematic reviews were also screened. Any reviews considered potentially relevant by authors were retrieved for further consideration.

Eligibility criteria

Eligible systematic reviews and meta-analyses included those (1) where patients were diagnosed with CKD at various stages of treatment; (2) that compared exercise interventions with sham/no exercise or usual/ standard care; (3) that reported outcomes on at least one of the following: cardiovascular risk factors (blood pressure), physical fitness, dialysis-related symptoms, dialysis adequacy and HRQOL. The methods to assess each outcome are shown in online supplemental figure S1 (4) systematic reviews with meta-analysis of intervention trials (RCTs and quasi-experimental studies). A meta-analysis that included fewer than 3 studies or fewer than 100 participants was excluded. For duplicate literature, the article with the most comprehensive data was selected. The language was restricted to English. Letters to the editor, trial protocols and conference abstracts were excluded.

Study selection

Two independent authors screened all titles and abstracts compiled from the search results. Each paper was examined for appropriate eligibility criteria, and a third author resolved disagreements.

Data extraction

Requisite data were extracted independently by two independent authors into a standardised format that included: (1) study, (2) stage of CKD, (3) the number of included studies and participants, (4) exercise type, (5) exercise mode (intradialytic or interdialytic), (6) standardised mean difference (SMD) or mean difference (MD) with corresponding 95% CI for each outcome, (7) p values, (8) \vec{l} values and (9) exercise-related adverse events.

Risk of bias assessment

A Measurement Tool to Assess Systematic Reviews-2 (AMSTAR-2) was used to assess the risk of bias among the included systematic reviews.¹⁹ This checklist contains 16 items, and each item was answered with a 'yes' (1 point), 'partial yes' (0.5 points) or 'no' (0 points). The percentage score for each study was calculated using the total score as the numerator and the highest score of 16 points as the denominator. A meta-analysis scoring $\geq 80\%$ was classified as high quality, 40%–79% as medium quality and those scoring <40% as low quality.²⁰ Two authors performed the risk of bias assessment independently, and discussions resolved the disagreement.

Data analysis

The summary effect size from each meta-analysis was analysed qualitatively based on the SMD and its 95% CI for each outcome. If they were not presented as SMD in the original meta-analysis, Review Manager V.5.3 was used to convert SMD outcomes. If data could not be converted into SMD, we contacted the authors of the meta-analysis for the data. Effects were considered small (SMD<0.50), moderate (SMD from 0.50 to 0.79) and large (SMD ≥ 0.80).²¹ \vec{r} values were interpreted as follows: $\leq 25\%$ indicate low heterogeneity, $25\% < \vec{r} \le 50\%$ indicate moderate heterogeneity and >75% indicate high heterogeneity.²²

The level of evidence for each meta-analysis was evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system.²³ The quality of evidence was assessed using five domains: risk of





Figure 1 Flow chart of literature screening. CDSR, Cochrane Database of Systemic Review.

bias, inconsistency, indirectness, imprecision and publication bias. Beginning with an initial score of 4 points, the score for each of these five domains was reduced accordingly: 'not reported (-1)', 'serious (-1)', 'very serious (-2)' or 'neutral (0)'. Studies were rated as high (4 points), moderate (3 points), low (2 points) or very low (≤ 1 point) using the GRADE system. The GRADE assessment was conducted independently by two authors. Any differences were resolved by discussion or adjudication by a third author. The incidence of adverse events was based on the number of reported divided by the patients in the exercise group.

RESULTS

Characteristics of the meta-analyses

The search identified 2305 potential articles, of which 648 were duplicates. After reading the title and abstract, 1598 papers were excluded and 28 were excluded after full-text review resulting in 31 final studies.¹⁰ ^{24–53} The PRISMA flow chart of study inclusion is illustrated in figure 1. The reasons for excluded articles are listed in online supplemental table S2.

The 31 included systematic reviews and meta-analyses were published from September 2011 through March 2021. The number of included studies assessed in the articles ranged from 3 to 24, with a mean of 8 studies. The study sample sizes ranged from 106 to 874 participants, with a mean of 304. The characteristics of the included meta-analyses are shown in online supplemental table S3. SMD data from four papers could not be obtained from the authors, and the data of their effect size were presented as MD.^{29 30 40 46}

Scores based on AMSTAR-2 ranged from 34.4% to 100.0%, with an average score of 68.0%. Seven (22.6%) systematic reviews were rated high quality, while 23 (74.2%) were rated medium quality, and just one (0.3%) was rated low quality (online supplemental table S4).

Of the GRADE evidence quality of the 120 outcomes, 1.7% (2/120) reported evidence of high quality, 17.5% (21/120) reported evidence of moderate quality, 20.0% (24/120) reported evidence of low quality and 60.8% (73/120) reported evidence of very low quality (online supplemental table S5).

Blood pressure

There were 25 meta-analyses (reported in 13 articles) investigating the effect of exercise on cardiovascular risk factors (systolic and diastolic blood pressure) in patients with CKD.^{10 27 30 33 34 40 41 43 46-49 52} Of which, the number of studies ranged from 3 to 12 with a mean of 314 participants (range from 198 to 514) were included in each meta-analysis (table 1).

The effect of exercise on systolic blood pressure was investigated in 13 meta-analyses with a mild heterogeneity (average l^2 =36.1%),^{10 27 30 33 34 40 41 43 46-49 52} and 6 reported a positive statistically significant outcome.³⁰³³⁴¹⁴³⁴⁹⁵² Of the 13 meta-analyses, 9 reported a small effect size ^{1027 33 34 41 43 47 48 52} and 1 reported moderate.⁴⁹ GRADE assessment of quality indicated the overall evidence as being very low (10 meta-analyses^{10 27 30 33 41 43 46-49}), low (2 meta-analyses^{34 40}) and moderate (1 meta-analysis⁵²).

The effect of exercise on diastolic blood pressure was investigated in 12 meta-analyses with a mild heterogeneity (average l^2 =49.1%),^{10 27 30 33 34 40 41 43 46-48 52} and 2 reported a positive statistically significant outcome.^{41 43} Of the 12 meta-analyses, 9 reported small effect sizes^{1027 33 34 41 43 47 48 52} and all were graded as low or very low quality of evidence.

Cardiorespiratory fitness

There were 34 meta-analyses (reported in 21 articles) that investigated the effects of exercise on cardiorespiratory fitness in patients with CKD using a peak oxygen uptake (18 of 34), a 6 min walk test (14 of 34) or aerobic capacity (2 of 34). The meta-analyses included a mean of 9 studies (ranging from 5 to 20) and a mean of 330 participants (ranging from 179 to 504) (table 2).

The effect of exercise on peak oxygen consumption was investigated in 18 meta-analyses (reported in 17 articles) with a mild heterogeneity (average $\mathring{r}=42.2\%$), 24252728303234373840414344495054 and 16 reported positive statistically significant outcomes. 242528303234373840414344474950 Of the 18 meta-analyses, 3 reported a low effect size, 27 39 50 9 reported a moderate effect size 25 28 32 34 37 41 43 44 49 and 3 reported a large effect size. 24 38 47 GRADE assessment of quality indicated the overall evidence as being very low (nine meta-analyses 25 27 28 30 32 37 43 47 49), low (eight meta-analyses 24 34 ${}^{38-41}$ 44 50) and high (one meta-analysis 37). A meta-analysis that included kidney transplant recipients found no statistically significant difference in the SMD of the exercise group (0.38; 95% CI: -0.06 to 0.82; p=0.09). 39

The effect of exercise on the 6 min walk test was investigated in 14 meta-analyses (reported in 13 articles) with a mild heterogeneity (average I^2 =44.9%), ²⁵ ²⁸⁻³⁰ ³² ³⁴ ³⁶⁻³⁸ ⁴⁰ ⁴¹ ⁴³ ⁵¹ and 13 reported positive statistically significant outcomes. ²⁵ ²⁸⁻³⁰ ³² ³⁴ ³⁶⁻³⁸ ⁴¹ ⁴³ ⁵¹ Of the 14 meta-analyses, 2 reported a small effect size, ²⁵ ²⁸ 5 reported a moderate effect size ³⁶ ³⁷ ⁴¹ ⁴³ ⁵¹ and 3 reported a large effect size. ³² ³⁴ ³⁸ GRADE assessment of quality indicated the overall evidence as being very low (eight meta-analyses²⁵ ³⁰ ³² ³⁴ ³⁸ ⁴⁰ ⁴³), low (four meta-analyses²⁸ ³⁷ ⁴¹ ⁵¹) and moderate (two meta-analyses²⁹ ³⁶). In addition, the meta-analysis by Heiwe and Jacobson¹⁰ showed that regular

exercise had significant beneficial effects on aerobic capacity.^{10 33}

Muscle strength

Ten meta-analyses (reported in nine articles) investigated the effects of exercise on muscle strength in patients with CKD with a low heterogeneity (average $l^2=19.1\%$).^{10 26 32 33 35–38 51} The meta-analyses included a mean of 7 studies (ranging from 3 to 12) and a mean of 252 participants (ranging from 115 to 385) (table 3).

Muscle strength was measured using handgrip strength and lower limb muscle strength. For patients in 8 of 10 meta-analyses, exercise resulted in statistically significant improvements in muscle strength.^{10 32 33 35–37 51} Of the 10 meta-analyses, 3 reported a small effect size,^{36 38 51} 5 reported a moderate effect size^{10 32 33 35 36} and 2 reported a large effect size.^{26 37} GRADE assessment of quality indicated the overall evidence as being very low (six metaanalyses^{10 32 33 35 37 38}) and low (four meta-analyses^{26 36 51}).

Muscle endurance

Nine meta-analyses (reported in eight articles) investigated the effects of exercise on muscle endurance with a mild heterogeneity (average $l^2=29.4\%$).^{10 25 33 36 38 40 43 51} An average of 238 participants (ranging from 106 to 461) from 5 studies (ranging from 3 to 7) were included in the meta-analysis (table 4).

Muscle endurance was measured using a sit-to-stand test, timed up and go test and walking capacity exercise. Pooled effect estimates from all nine meta-analyses suggested a beneficial effect of exercise on muscle endurance in patients with CKD. Seven of the nine meta-analyses reported power to detect a statistically significant effect.^{25 33 36 38 43 51} Two meta-analyses reported moderate effect size and five reported small effect size. GRADE assessment of quality indicated the overall evidence as being very low (seven meta-analyses^{25 33 6 38 40 43 51}), low (one meta-analyses³⁶) and moderate (one meta-analyses¹⁰).

Body composition

Four meta-analyses consisting of 9 studies (ranging from 4 to 13) and a mean of 335 participants (ranging from 166 to 466) included body mass index as an outcome.^{27 47 49 52} There was a low heterogeneity (average l^2 =12.0%) among the study outcomes (table 5).

Three of the four meta-analyses showed a positive statistically significant impact on body mass index using exercise interventions in patients with CKD.^{47 49 52} Small effect size was reported in all meta-analyses. GRADE assessment of quality indicated the overall evidence as being very low (one meta-analysis), low (two meta-analyses^{47 49}) and moderate (one meta-analysis⁵²).

Dialysis-related symptoms

Nine meta-analyses (reported in seven articles) investigated the effect of exercise on dialysis-related symptoms in patients with CKD.^{30 31 34 41 43 45 53} Each meta-analysis included a mean of 7 studies (ranging from 3 to 12

Sign of the set of	Study	Design	Stage of CKD	k (n)*	Exercise type	Mode	SMD or MD (95% CI)	Effect size	P value	β ²	GRADE
Per et all ECT/Ouasi-FCT Mode $12(514)$ AE MD: $-291(6.6910.037)$ 013 0106 000 Out at all ECT/Ouasi-FCT Prediaysis $5(20)$ $AE+HT$ SMD: $-19(6,0100.043)$ Small 013 0006 0003	SBP										
Wu et aff* ECT/Quasi-RCT Peediaysis 3 (2) AE+IT - SMD: -0.13 (-0.46) Small 0.15 50.00 60 Cure at aff* ECT KT KT 5 (139) Maded - SMD: -0.13 (-0.16) Small 0.22 0.05 60 Cure at aff* ECT FCT Prediaysis 10 (332) Maded - SMD: -0.13 (-0.16) Small 0.02 0.03 60 (30 60 Tamamoto et aff* ECT Prediaysis 10 (332) Maded - SMD: -0.14 (-0.100) Small 0.02 0.03 60 (30 60	Pei <i>et al</i> ⁴⁰	RCT/Quasi-RCT	Mixed	12 (514)	AE	I	MD: -2.91 (-6.68 to 0.87)	I	0.13	40.0%	$\bigcirc \bigcirc \oplus \oplus \bigcirc$
Chene at	Wu <i>et al</i> ⁴⁸	RCT/Quasi-RCT	Predialysis	3 (204)	AE+RT	I	SMD: -0.19 (-0.46 to 0.08)	Small	0.16	50.0%	0 00 ⊕
Pet at " ECT HD 7(287) Mised Intradisiyite SMD: -0.28 (-0.026) Small 0.02 0.04 9.04 Ymmento et al" RCT Peediaysis 10(329) Mised - SMD: -0.75 (-1.2410.026) Moderate 0.00 6.036 6.046 Ymmento et al" RCT Peediaysis 10(329) Mised - SMD: -0.17 (-0.411 to 0.03) Small 0.00 6.056 6.05 Hung et al" RCT HD 7(260) Mised - SMD: -0.17 (-0.411 to 0.03) Small 0.01 5.046 6.0 Hung et al" RCT HD 7(260) Mised - SMD: -0.41 (-0.103) Small 0.02 0.03 6.0 6.0 Hung et al" RCT HD 10(322) Mised - SMD: -0.41 (-0.103) Small 0.02 0.03 6.0 6.0 Hung et al" RCT HD 10(322) Mised MD 0.01 (-0.41 to 0.03) Small 0.02 0.03	Chen <i>et al²⁷</i>	RCT	KTRs	5 (198)	Mixed	I	SMD: 0.18 (-0.10 to 0.46)	Small	0.21	0.0%	000€
Termenote at affection ECT Preclaysis 10 (335) Mise SMD:0.75 (-1.24 to 0.26) Modemie 0.003 80.35 90.35	Pu <i>et al</i> ⁴¹	RCT	Я	7 (287)	Mixed	Intradialytic	SMD: -0.28 (-0.52 to 0.05)	Small	0.02	0.0%	0 00 ⊕
Thompson et all ECT Prediaysis 10 (335) Mixed - MD: -430 (400 to 0.40) - ND:	Yamamoto <i>et al⁴⁹</i>	RCT	Predialysis	10 (392)	AE	I	SMD: -0.75 (-1.24 to 0.26)	Moderate	0.003	80.3%	0 00 ⊕
Zhang et aff E(T) Pedialysis 14(45) Mixed $$ SMD: -0.17 (-0.710 0.11) Small 0.007 55.0% -0.07 Hung et aff E(T) HD 7 (260) Mixed $$ SMD: -0.17 (-0.110 0.01) Small 0.02 0.03 -0.05 -0.05 Henra et aff E(T) HD 10 (312) Mixed $$ SMD: -0.17 (-0.110 0.11) Small 0.02 0.03 -0.05 -0.05 Henra et aff E(T) HD 10 (312) Mixed $$ SMD: -0.17 (-0.110 0.11) Small 0.02 0.03 -0.05	Thompson <i>et al</i> ⁴⁶	RCT	Predialysis	10 (335)	Mixed	I	MD: -4.30 (-9.00 to 0.40)	I	N.P.	50.4%	000€
Huang et al ⁴ ECT HD 7 (260) Mixed SMD: -0.17 (0.41 to 0.08) Small 0.18 8.0% Θ Hewe et al ⁴ RCT/Quasi-ICT Mixed 9(347) Mixed - SMD: 0.4 (0.41 to 0.08) Small 0.02 0.0% Θ Hewe et al ⁴ RCT/Quasi-ICT Mixed 9(347) Mixed - SMD: 0.4 (0.34 to 0.47) Small 0.02 0.0% Θ Hewe and Jacobson ¹⁰ RCT HD 10 (312) Mixed - SMD: 0.4 (0.34 to 0.47) Small 0.02 0.0% Θ Sheng et al ⁴ RCT HD 10 (312) Mixed - SMD: 0.04 (0.34 to 0.47) Small 0.02 0.0% Θ Sheng et al ⁴ RCT HD 10 (322) AE - SMD: 0.04 (0.34 to 0.7) Small 0.01 200% Θ Vorte al ⁴ RCT ND -10 (0.104 to 0.5) Small 0.12 700% Θ Vanden Wyngaet et al ⁴ RCT/Quasi-RCT	Zhang et af ⁵²	RCT	Predialysis	14 (463)	Mixed	I	SMD: -0.41 (-0.70 to 0.11)	Small	0.007	55.0%	⊖⊕⊕⊕
Heiwe et a ¹ RCT/Quasi-RCT Mixed 9(37) Mixed - SMD: 0.25 (0.04 to 0.47) Small 0.02 0.04 $\oplus O$ Heiwe and Jacobson ¹ RCT HD 10(312) Mixed - SMD: 0.04 (0.34 to 0.47) Small 0.02 0.04 $\oplus O$ Sheng et a ¹ RCT HD 10(312) Mixed - SMD: 0.04 (0.34 to 0.47) Small 0.02 0.04 $\oplus O$ Sheng et a ¹ RCT HD 10(312) Mixed - SMD: 0.04 (0.34 to 0.47) Small 0.02 0.04 $\oplus O$ Ferrait et a ¹ RCT HD 10(322) AE - SMD: 0.04 (0.34 to 0.47) Small 0.02 0.04 $\oplus O$ Verter a ¹ RCT HD 10(322) AE - SMD: 0.04 (0.41) Small 0.02 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05	Huang <i>et al</i> ³⁴	RCT	Я	7 (260)	Mixed	Mixed	SMD: -0.17 (-0.41 to 0.08)	Small	0.18	8.0%	$\Theta \oplus \Theta$
Heive and Jacobson ¹⁰ ECT HD 10 (312) Mixed $$ SMD: 0.024 (0.34 to 0.41) Small 0.82 68.0% 0 Sheng et a ^{1/2} RCT HD 7 (296) Mixed Intradialytic SMD: -0.27 (-0.56 to 0.04) Small 0.02 0.0% -0.0 Ferrai et a ^{1/2} RCT HD 10 (332) AE Intradialytic SMD: -0.27 (-0.56 to 0.04) Small 0.02 0.0% -0.0 Vanden Wyngaert et a ^{1/2} RCT Pedialysis 8 (269) AE - SMD: -0.07 (16.35 to 3.76) - 0.02 0.0% -0.0 Vanden Wyngaert et a ^{1/2} RCT Pedialysis 8 (269) AE - SMD: -0.17 (-1.10 to 0.15) Small 0.01 0.02 0.0% -0.0 Vu et a ^{1/2} RCT Predialysis 4 (194) AE+HT - SMD: -0.17 (-1.10 to 0.15) Small 0.01 0.03 9.09 9.09% -0.0 Vu et a ^{1/2} RCT RCT NE - SMD:	Heiwe <i>et al</i> ³³	RCT/Quasi-RCT	Mixed	9 (347)	Mixed	I	SMD: 0.25 (0.04 to 0.47)	Small	0.02	0.0%	000€
Sheng et a rd RCT HD 7 (296) Mixed Intradialytic SMD: -0.27 (-0.50 to 0.04) Small 0.02 0.04% $\oplus \odot$ Ferariet a rd RCT HD 10 (332) AE Intradialytic MD: -10.07 (16.35 to 3.73) 0.002 44.0% $\oplus \odot$ Vanden Wyngaert et a rd RCT Predialysis 8 (269) AE - SMD: 0.08 (-0.58 to 0.74) Small 0.81 84% $\oplus \odot$ De presenter a rd RCT/ouasi-RCT Mixed 12 (514) AE - Small 0.81 84% $\oplus \odot$ De var a rd RCT/ouasi-RCT Mixed 12 (514) AE - Small 0.11 70% $\oplus \odot$ Uva et a rd RCT/Ouasi-RCT Mixed 12 (514) AE - Small 0.14 70% $\oplus \odot$ Uva et a rd RCT/Ouasi-RCT Precialysis 1 (194) Mixed - 11 (1-10 (101)) Small 0.11 70% $\oplus \odot$ Uva et a rd RC	Heiwe and Jacobson ¹⁰	RCT	Я	10 (312)	Mixed	I	SMD: 0.04 (-0.34 to 0.41)	Small	0.8	58.0%	⊖₁⊕
Ferrariet af ⁰ RCT HD 10(322) AE Intradialytic MD: -10.07 (16.35 to 3.78) - 0.002 44.0% ϕ Vanden Wyngeent et af ⁴ RCT Pedialysis 8 (269) AE - SMD: 0.08 (-0.58 to 0.74) Small 0.81 84% ϕ DBP Karden Wyngeent et af ⁴ RCT Predialysis 8 (269) AE - SMD: 0.047 (15.35 to 3.78) - 0.031 84% ϕ DBP Karden Wyngeent et af ⁶ RCT/Quasi-RCT Mixed 12 (514) AE - SMD: 0.047 (15.10 to 0.15) Small 0.14 70.0% ϕ Vu et af ⁶ RCT HD 7 (281) Mixed - SMD: 0.04 (-0.45 to 0.25) Small 0.04 0.06 ϕ 0.06 ϕ 0.04 0.05 Small 0.04 0.05 Small 0.04 0.05 Small 0.04 0.05 Small 0.04 0.05 0.04 0.05 MD 0.06 MD 0.04 0.07	Sheng <i>et al</i> ⁴³	RCT	Я	7 (296)	Mixed	Intradialytic	SMD: -0.27 (-0.50 to 0.04)	Small	0.02	0.0%	000€
Vanden Wyngaert et al ⁴ RCT Preclakysis 8 (269) AE - SMD: 0.08 (-0.58 to 0.74) Small 0.31 84% \oplus DBP <td>Ferrari <i>et a/</i>³0</td> <td>RCT</td> <td>무</td> <td>10 (332)</td> <td>AE</td> <td>Intradialytic</td> <td>MD: -10.07 (16.35 to 3.78)</td> <td>I</td> <td>0.002</td> <td>44.0%</td> <td>000€</td>	Ferrari <i>et a/</i> ³0	RCT	무	10 (332)	AE	Intradialytic	MD: -10.07 (16.35 to 3.78)	I	0.002	44.0%	000€
DBP FCT/Ouasi-RCT Mixed 12(514) AE - MD: -1.11(-3.4110120) - 0.35 0.0% 60% Petet aft ⁰ RCT/Ouasi-RCT Mixed 12 - ND: -0.47(-1.10 to 0.15) Small 0.14 70.0% 60% We tet aft ⁰ RCT/Ouasi-RCT Predialysis 1(94) AE+RT - SMD: -0.47(-1.10 to 0.15) Small 0.14 70.0% 60% We tet aft ⁰ RCT HD 7 (287) Mixed - SMD: -0.32(-0.55 to 0.08) Small 0.14 70.0% 60% Unompose ta aft ⁰ RCT Predialysis 8(303) Mixed - SMD: -0.31 (-0.14 to 0.52) Small 0.014 20.0% 60% Unompose ta aft ¹ RCT Predialysis 8(303) Mixed - SMD: -0.31 (-0.140 0.03) Small 0.014 20.0% 60% Unompose ta aft ² RCT Huang et aft ² Mixed - SMD: -0.31 (-0.14 0.03) Small 0.01 20	Vanden Wyngaert et al ⁴⁷	RCT	Predialysis	8 (269)	AE	I	SMD: 0.08 (-0.58 to 0.74)	Small	0.81	84%	000€
Peter a^{4} RCT/Quasi-RCT Mixed $12(514)$ AE - MD: -1.11(-3.4110120) - 0.35 0.0% 960 Wu et a^{f} RCT/Quasi-RCT Predialysis 4(194) AE+RT - SMD: -0.47(-1.1010.015) Small 0.14 70.0% 960 Wu et a^{f} RCT KTRs 5(196) Mixed - SMD: 0.04(-0.4510.052) Small 0.14 70.0% 960 Chen et a^{f} RCT HD 7(287) Mixed - SMD: 0.04(-0.4510.052) Small 0.14 70.0% 960 Thompsonet a^{f} RCT Predialysis 8(303) Mixed - SMD: 0.01(-0.15) Small 0.12 70.0% 900 Thompsonet a^{f} RCT Predialysis 8(303) Mixed - SMD: 0.01(-0.160.0.15) Small 0.12 70.0% 900 Thompsonet a^{f} RCT Predialysis 8(303) Mixed - SMD: -0.17(-0.100.015) Small 0.12 70.0	DBP										
We tet a^{4} RCT/Quasi-RCT Predialysis 4(194) AE+RT - SMD: -0.47 (-1.10 to 0.15) Small 0.14 70.0% $\oplus O$ Chen et a^{f} RCT KTRs 5 (198) Mixed - SMD: -0.32 (-0.55 to 0.52) Small 0.14 70.0% $\oplus O$ Pu et a^{f} RCT HD 7 (287) Mixed - SMD: -0.32 (-0.55 to 0.08) Small 0.18 20.0% $\oplus O$ Pu et a^{f} RCT Predialysis 8 (303) Mixed - SMD: -0.32 (-0.55 to 0.08) Small 0.12 70.0% $\oplus O$ Tompson et a^{f} RCT Predialysis 8 (303) Mixed - SMD: -0.16 (-0.74) Small 0.12 70.0% $\oplus O$ Tompson et a^{f} RCT HD 7 (280) Mixed - SMD: -0.16 (-0.14) Small 0.12 70.0% $\oplus O$ Huang et a^{f} RCT HD 7 (260) Mixed SMD: -0.23 (-0.69 to 0.24) Small 0.11 40.0% </td <td>Pei <i>et al</i>⁴⁰</td> <td>RCT/Quasi-RCT</td> <td>Mixed</td> <td>12 (514)</td> <td>AE</td> <td>I</td> <td>MD: -1.11 (-3.41 to 1.20)</td> <td>I</td> <td>0.35</td> <td>0.0%</td> <td>$\bigcirc \bigcirc \oplus \oplus \bigcirc$</td>	Pei <i>et al</i> ⁴⁰	RCT/Quasi-RCT	Mixed	12 (514)	AE	I	MD: -1.11 (-3.41 to 1.20)	I	0.35	0.0%	$\bigcirc \bigcirc \oplus \oplus \bigcirc$
Chen et $a^{r/3}$ RCT KTRs 5 (198) Mixed - SMD: 0.04 (-0.45 to 0.52) Small 0.39 59.0% \oplus Pu et $a^{r/1}$ RCT HD 7 (287) Mixed - SMD: -0.32 (-0.55 to 0.08) Small 0.09 42.0% \oplus Pu et $a^{r/1}$ RCT HD 7 (287) Mixed - SMD: -0.32 (-0.55 to 0.08) Small 0.09 42.0% \oplus Thompson et $a^{r/6}$ RCT Precialysis 12 (399) Mixed - SMD: -0.118 (-1.71 to 0.08) Small 0.12 70.0% \oplus Thompson et $a^{r/6}$ RCT HD 7 (280) Mixed - SMD: -0.21 (-0.71 to 0.08) Small 0.12 70.0% \oplus Huang et $a^{r/6}$ RCT HD 7 (280) Mixed - SMD: -0.24 (-0.47 to 0.03) Small 0.11 40.0% \oplus	Wu et a/⁴8	RCT/Quasi-RCT	Predialysis	4 (194)	AE+RT	I	SMD: -0.47 (-1.10 to 0.15)	Small	0.14	70.0%	0 00 ⊕
Image:	Chen <i>et al</i> ²⁷	RCT	KTRs	5 (198)	Mixed	I	SMD: 0.04 (-0.45 to 0.52)	Small	0.89	59.0%	0 00 ⊕
Thompson et al^6RCTPredialysis8 (303)Mixed-MD: -1.18 (-1.76 to 2.40)-N.P.60.5% $\oplus \odot$ Zhang et al^62RCTPredialysis12 (399)Mixed-SMD: -0.31 (-0.71 to 0.08)Small0.1270.0% $\oplus \oplus$ Uhang et al^62RCTHD7 (260)Mixed-SMD: -0.23 (-0.69 to 0.24)Small0.1270.0% $\oplus \oplus$ Huang et al^43RCT/Quasi-RCTMixed11 (419)Mixed-SMD: 0.16 (-0.04 to 0.36)Small0.1140.0% $\oplus \odot$ Heiwe et al^83RCT/Quasi-RCTMixed11 (419)Mixed-SMD: 0.17 (-0.16 to 0.49)Small0.1140.0% $\oplus \odot$ Heiwe and Jacobson ¹⁰ RCTHD10 (212)Mixed-SMD: 0.17 (-0.16 to 0.49)Small0.34 68.0% $\oplus \odot$ Sheng et al^83RCTHD7 (296)MixedIntradialyticSMD: 0.17 (-0.16 to 0.49)Small0.34 60.7% $\oplus \odot$ Sheng et al^80RCTHD7 (296)MixedIntradialyticSMD: 0.17 (-0.16 to 0.49)Small0.04 52.1% $\oplus \odot$ Ferrari et al ⁸⁰ RCTHD10 (334)AEIntradialyticSMD: -0.24 (-0.47 to 0.01)Small0.04 52.1% $\oplus \odot$ Vanden Wyngaert et al ⁸⁰ RCTHD10 (334)AE-0.09 (-0.78 to 0.59)Small0.79 $\odot 0.0\%$ $\oplus \odot$	Pu <i>et al</i> ⁴¹	RCT	Я	7 (287)	Mixed	Intradialytic	SMD: -0.32 (-0.55 to 0.08)	Small	0.008	42.0%	0 00 ⊕
Zhang et a^{62} RCT Predialysis 12 (399) Mixed - SMD: -0.31 (-0.71 to 0.08) Small 0.12 70.0% $\oplus \oplus $	Thompson <i>et al</i> ⁴⁶	RCT	Predialysis	8 (303)	Mixed	I	MD: -1.18 (-4.76 to 2.40)	I	N.P.	60.5%	000€
Huang et a^{34} RCT HD 7 (260) Mixed SMD: -0.23 (-0.69 to 0.24) Small 0.34 68.0% $\oplus \bigcirc$ Heiwe et a^{33} RCT/Quasi-RCT Mixed 11 (419) Mixed - SMD: 0.16 (-0.04 to 0.36) Small 0.11 40.0% $\oplus \bigcirc$ Heiwe et a^{73} RCT HD 10 (212) Mixed - SMD: 0.17 (-0.16 to 0.39) Small 0.11 40.0% $\oplus \bigcirc$ Sheng et a^{73} RCT HD 10 (212) Mixed Mixed SMD: 0.17 (-0.16 to 0.39) Small 0.3 45.0% $\oplus \bigcirc$ Sheng et a^{73} RCT HD 7 (296) Mixed Intradialytic SMD: -0.24 (-0.47 to 0.01) Small 0.04 $\odot \bigcirc$ Ferrari et a^{90} RCT HD 7 (236) AE Intradialytic SMD: -2.06 (-7.71 to 1.78) $\circ = 0.22$ 0.0% $\oplus \bigcirc$ Vanden Wyngaert et a^{10} RCT HD 7 (237) AE $- 0.09 (-0.78 to 0.59)$ $Small$ 0.22 0.0% $\odot \bigcirc \odot$	Zhang et al ⁵²	RCT	Predialysis	12 (399)	Mixed	I	SMD: -0.31 (-0.71 to 0.08)	Small	0.12	70.0%	$\Theta \oplus \Theta$
Heiwe et a^{33} RCT/Quasi-RCT Mixed 11 (419) Mixed - SMD: 0.16 (-0.04 to 0.36) Small 0.11 40.0% $\oplus \bigcirc$ Heiwe and Jacobson ¹⁰ RCT HD 10 (212) Mixed Mixed SMD: 0.17 (-0.16 to 0.49) Small 0.3 45.0% $\oplus \oplus$ Sheng et a^{43} RCT HD 7 (296) Mixed Intradialytic SMD: -0.24 (-0.47 to 0.01) Small 0.04 52.1% $\oplus \bigcirc$ Ferrari et a^{60} RCT HD 7 (296) Mixed Intradialytic SMD: -0.24 (-0.47 to 0.01) Small 0.04 52.1% $\oplus \bigcirc$ Vanden Wyngaert et a^{60} RCT HD 10 (334) AE Intradialytic MD: -2.96 (-7.71 to 1.78) - 0.022 0.0% $\oplus \bigcirc$	Huang <i>et al</i> ³⁴	RCT	Я	7 (260)	Mixed	Mixed	SMD: -0.23 (-0.69 to 0.24)	Small	0.34	68.0%	000€
Heiwe and Jacobson ¹⁰ RCT HD 10 (212) Mixed SMD: 0.17 (-0.16 to 0.49) Small 0.3 45.0% $\oplus 0$ Sheng et $a/^4$ RCT HD 7 (296) Mixed Intradialytic SMD: -0.24 (-0.47 to 0.01) Small 0.3 45.0% $\oplus 0$ Ferrari et $a/^6$ RCT HD 7 (296) Mixed Intradialytic SMD: -0.24 (-0.47 to 0.01) Small 0.04 52.1% $\oplus 0$ Vanden Wyngaert et $a/^4$ RCT HD 10 (334) AE Intradialytic MD: -2.96 (-7.71 to 1.78) - 0.22 0.0% $\oplus 0$ Vanden Wyngaert et $a/^4$ RCT Predialysis 7 (237) AE - SMD: -0.09 (-0.78 to 0.59) Small 0.79 83% $\oplus 0$	Heiwe <i>et al</i> ³³	RCT/Quasi-RCT	Mixed	11 (419)	Mixed	I	SMD: 0.16 (-0.04 to 0.36)	Small	0.11	40.0%	000€
Sheng <i>et al</i> ⁴³ RCT HD 7 (296) Mixed Intradialytic SMD: -0.24 (-0.47 to 0.01) Small 0.04 52.1% ⊕O Ferrari <i>et al</i> ⁶⁰ RCT HD 10 (334) AE Intradialytic MD: -2.96 (-7.71 to 1.78) - 0.22 0.0% ⊕O Vanden Wyngaert <i>et al</i> ⁴⁷ RCT Predialysis 7 (237) AE - SMD: -0.09 (-0.78 to 0.59) Small 0.79 83% ⊕O	Heiwe and Jacobson ¹⁰	RCT	머	10 (212)	Mixed	Mixed	SMD: 0.17 (-0.16 to 0.49)	Small	0.3	45.0%	$\bigcirc \bigcirc \oplus \oplus \bigcirc 0 \bigcirc 0$
Ferrari <i>et al</i> ³⁰ RCT HD 10 (334) AE Intradialytic MD: -2.96 (-7.71 to 1.78) - 0.22 0.0% ⊕O(Vanden Wyngaert <i>et al</i> ⁴⁷ RCT Predialysis 7 (237) AE - SMD: -0.09 (-0.78 to 0.59) Small 0.79 83% ⊕O(Sheng et a/ ⁴³	RCT	Я	7 (296)	Mixed	Intradialytic	SMD: -0.24 (-0.47 to 0.01)	Small	0.04	52.1%	000€
Vanden Wyngaert et al ⁴⁷ RCT Predialysis 7 (237) AE – SMD: –0.09 (-0.78 to 0.59) Small 0.79 83% \oplus O	Ferrari <i>et al</i> ³⁰	RCT	Я	10 (334)	AE	Intradialytic	MD: -2.96 (-7.71 to 1.78)	I	0.22	0.0%	000€
	Vanden Wyngaert et al ⁴⁷	RCT	Predialysis	7 (237)	AE	I	SMD: -0.09 (-0.78 to 0.59)	Small	0.79	83%	000€

Table 2 Summary of	the effect of exer-	cise on cardiopul	monary fitr	ness in patients	with CKD					
Study	Design	Stage of CKD	k (n)*	Exercise type	Mode	SMD or MD (95% CI)	Effect size	P value	P ²	GRADE
VO _{2 peak}										
Pei et al ⁴⁰	RCT/Quasi-RCT	Mixed	17 (464)	AE	I	MD: 2.08 (1.10 to 3.05)	I	<0.001	25.0%	$\bigcirc \bigcirc \oplus \oplus \bigcirc$
Nakamura <i>et al</i> ³⁸	RCT/Cross-over	Predialysis	10 (401)	Mixed	I	SMD: 0.88 (0.53 to 1.23)	Large	<0.001	56.0%	$\bigcirc \bigcirc \oplus \oplus \bigcirc$
Chen <i>et al²⁷</i>	RCT	KTRs	6 (202)	Mixed	I	SMD: 0.33 (-0.02 to 0.69)	Small	0.06	27.0%	⊕ 000
Andrade <i>et al</i> ²⁴	RCT	П	5 (201)	AE+RT	Intradialytic	SMD: 1.01 (0.71 to 1.30)	Large	<0.001	0.0%	$\bigcirc \bigcirc \oplus \oplus \bigcirc$
Chung <i>et al</i> ²⁸	RCT	ЧH	6 (238)	Mixed	Intradialytic	SMD: 0.55 (0.18 to 0.92)	Moderate	0.003	52.9%	000⊕
Pu <i>et al</i> ⁴¹	RCT	Я	10 (400)	Mixed	Intradialytic	SMD: 0.57 (0.23 to 0.90)	Moderate	<0.001	59.0%	$\bigcirc \bigcirc \oplus \oplus$
Yamamoto <i>et al⁴⁹</i>	RCT	Predialysis	10 (365)	AE	I	SMD: 0.54 (0.29 to 0.78)	Moderate	<0.001	24.6%	000⊕
Yang <i>et al</i> ⁵0	RCT	Mixed	5 (179)	Mixed	I	SMD: 0.33 (0.03 to 0.63)	Small	0.003	47.0%	$\bigcirc \bigcirc \oplus \oplus \bigcirc$
Huang <i>et al</i> ³⁴	RCT	П	10 (371)	Mixed	Mixed	SMD: 0.73 (0.52 to 0.95)	Moderate	<0.001	71.0%	$\bigcirc \bigcirc \oplus \oplus \bigcirc \bigcirc \bigcirc \bigcirc \oplus \oplus \bigcirc \bigcirc \bigcirc \bigcirc \bigcirc \bigcirc \bigcirc \bigcirc \bigcirc \bigcirc$
Matsuzawa <i>et al³⁷</i>	RCT	Π	18 (582)	Mixed	Mixed	SMD: 0.62 (0.38 to 0.87)	Moderate	<0.001	49.0%	$\oplus \oplus \oplus \oplus$
Smart et al ⁴⁴	RCT	Я	8 (365)	Mixed	Mixed	SMD: 0.75 (0.39 to 1.11)	Moderate	<0.001	60.0%	$\bigcirc \bigcirc \oplus \oplus \bigcirc$
Bogataj <i>et al²⁵</i>	RCT	Π	20 (504)	Mixed	Mixed	SMD: 0.58 (0.32 to 0.85)	Moderate	<0.001	57.4%	⊕ 000
Sheng <i>et al</i> ⁴³	RCT	Π	7 (310)	Mixed	Intradialytic	SMD: 0.53 (0.30 to 0.76)	Moderate	<0.001	36.0%	000 ⊕
Neto <i>et al</i> ³²	RCT	Π	10 (394)	Mixed	Intradialytic	SMD: 0.60 (0.15 to 1.04)	Moderate	0.008	76.0%	000 ⊕
Ferrari <i>et a/</i> ³0	RCT	Π	5 (201)	AE+RT	Intradialytic	MD: 5.41 (4.03 to 6.79)	I	<0.001	0.0%	000 ⊕
Ferrari <i>et a/</i> ³0	RCT	Π	7 (248)	AE	Intradialytic	MD: 2.07 (0.42 to 3.72)	I	<0.001	0.0%	000 ⊕
Vanden Wyngaert et al ⁴⁷	RCT	Predialysis	11 (325)	AE	1	SMD: 0.99 (0.49 to 1.48)	Large	<0.001	74.0%	000 ⊕
Oguchi <i>et al</i> ³⁹	RCT	KTRs	4 (182)	Mixed	I	SMD: 0.38 (-0.06 to 0.82)	Small	0.09	45.0%	$\bigcirc \bigcirc \oplus \oplus \bigcirc$
6MWT										
Pei et al ⁴⁰	RCT/Quasi-RCT	Mixed	8 (496)	AE	I	MD: 0.04 (-0.52 to 0.59)	I	0.90	86.0%	⊕ 000
Nakamura et al ³⁸	RCT/Cross-over	Predialysis	5 (392)	Mixed	I	SMD: 1.04 (0.17 to 1.90)	Large	0.02	92.0%	Ф000
Lu <i>et al</i> ³⁶	RCT	Dialysis	11 (300)	Mixed	Mixed	SMD: 0.52 (0.31 to 0.72)	Moderate	<0.001	39.0%	⊖⊕⊕⊕
Chung <i>et a/</i> ² ⁸	RCT	НD	4 (127)	Mixed	Intradialytic	SMD: 0.44 (0.09 to 0.80)	Small	0.015	0.0%	$\bigcirc \bigcirc \oplus \oplus \bigcirc$
Zhang et al ⁵¹	RCT	HD	8 (299)	RT	Intradialytic	SMD: 0.52 (0.28 to 0.75)	Moderate	<0.001	18.7%	$\bigcirc \bigcirc \oplus \oplus \bigcirc$
Pu et al ⁴¹	RCT	HD	7 (219)	Mixed	Intradialytic	SMD: 0.57 (0.30 to 0.84)	Moderate	<0.001	0.0%	$\bigcirc \bigcirc \oplus \oplus \bigcirc$
Clarkson <i>et al²</i>	RCT	Dialysis	18 (744)	Mixed	I	MD: 33.64 (23.74 to 43.54)	I	<0.001	0.0%	⊖⊕⊕⊕
Huang et a/ ³⁴	RCT	HD	7 (205)	Mixed	Mixed	SMD: 1.01 (0.26 to 1.76)	Large	0.008	83.0%	000⊕
Matsuzawa <i>et al³⁷</i>	RCT	Н	10 (326)	Mixed	Mixed	SMD: 0.58 (0.24 to 0.93)	Moderate	<0.001	53.0%	$\bigcirc \bigcirc \oplus \oplus \bigcirc$
Bogataj <i>et al²⁵</i>	RCT	П	19	Mixed	Mixed	SMD: 0.44 (0.21 to 0.67)	Small	<0.001	49.6%	⊕ 000
Sheng <i>et al</i> ⁴³	RCT	Π	4 (146)	Mixed	Intradialytic	SMD: 0.58 (0.23 to 0.93)	Moderate	<0.001	89.7%	⊕ 000
Neto et al ³²	RCT	Π	6 (158)	Mixed	Intradialytic	SMD: 0.96 (0.11 to 1.80)	Large	0.03	82.0%	Ф000
Ferrari et a/³0	RCT	HD	6 (211)	RT	Intradialytic	MD: 68.5 (29.05 to 107.96)	I	<0.001	36.0%	⊕ ○○
Ferrari et a/ ³⁰	RCT	ЧH	6 (188)	AE	Intradialytic	MD: 64.98 (43.86 to 86.11)	1	<0.001	0.0%	⊕ ○○○
										Continued

6

6

Table 2 Continued										
Study	Design	Stage of CKD	k (n)*	Exercise type	Mode	SMD or MD (95% CI)	Effect size	P value	β2	GRADE
Aerobic capacity										
Heiwe <i>et al</i> ³³	RCT/Quasi-RCT	Mixed	24 (847)	Mixed	I	SMD: -0.56 (-0.70 to 0.42)	Moderate	<0.001	12.0%	000 ⊕
Heiwe and Jacobson ¹⁰	RCT	Н	21 (374)	Mixed	Mixed	SMD: -0.80 (-1.02 to 0.58)	Large	<0.001	%0.0	$\bigcirc \bigcirc \oplus \oplus \bigcirc$
Mixed means aerobic exerc *Number of included studie: AE, aerobic exercise; CKD, 6min walk test; RCT, randor	ise combined with resis s and corresponding sat shronic kidney disease; nised controlled trial; R1	tance training. mple size. GRADE, Gradingof Re T, resistance training; S	ecommendati MD, standarc	ons Assessment, Dev dised mean difference	/elopment and E/ s; VO _{2 peak} , peak o	raluation; HD, haemodialysis; KTRs, ki xygen uptake.	idney transplant rec	ipients; MD, m	nean differenc	

Table 3 Summary c	of the effect of exer	cise on muscle st	trength in p	oatients with CK	D					
Study	Design	Stage of CKD	k (n)*	Exercise type	Mode	SMD or MD (95% CI)	Effect size	P value	J ²	GRADE
Cheema <i>et al²⁶</i>	RCT	Predialysis	7 (249)	RT	1	SMD: 1.15 (0.80 to 1.49)	Large	0.161	35.0%	$\Theta \oplus \Theta \bigcirc$
Nakamura et al ³⁸	RCT/Cross-over	Predialysis	4 (119)	Mixed	I	SMD: 0.35 (-0.03 to 0.73)	Small	0.07	7.0%	000€
Lu <i>et al</i> ³⁶	RCT	Dialysis	5 (234)	Mixed	Mixed	SMD: 0.59 (0.20 to 0.98)	Moderate	0.003	52.0%	$\bigcirc\bigcirc\oplus\oplus$
Lu <i>et al</i> ³⁶	RCT	Dialysis	7 (224)	Mixed	Mixed	SMD: 0.47 (0.20 to 0.74)	Small	<0.001	0.0%	$\bigcirc\bigcirc\oplus\oplus$
Zhang et a/ ⁵¹	RCT	ЧD	6 (300)	RT	Intradialytic	SMD: 0.35 (0.12 to 0.58)	Small	0.003	41.6%	$\bigcirc\bigcirc\oplus\oplus$
Heiwe et a/ ³³	RCT/Quasi-RCT	Mixed	9 (358)	Mixed	I	SMD: -0.52 (-0.73 to 0.31)	Moderate	<0.001	0.0%	000€
Heiwe and Jacobson ¹⁰	RCT	ЧD	12 (385)	Mixed	Mixed	SMD: -0.56 (-0.77 to 0.35)	Moderate	<0.001	0.0%	000€
Matsuzawa et al ³⁷	RCT	П	9 (281)	Mixed	Mixed	SMD: 0.94 (0.67 to 1.21)	Large	<0.001	10.0%	000₽
Neto <i>et al</i> ³²	RCT	П	9 (250)	Mixed	Intradialytic	SMD: 0.61 (0.39 to 0.83)	Moderate	<0.001	58.9%	000€
Ju <i>et al</i> ³⁵	RCT	Mixed	3 (115)	Mixed	1	SMD: 0.52 (0.14 to 0.89)	Moderate	0.007	%0.0	0 00 ⊕
Mixed means aerobic exerc	ise combined with resist	tance training.								

.

. . . .

"Number of included studies and corresponding sample size. CKD, chronic kidney disease; GRADE, Grading of Recommendations Assessment, Development and Evaluation; HD, haemodialysis; MD, mean difference; RCT, randomised controlled trial; RT, resistance training; SMD, standardised mean difference.

Table 4 Summar	y of the effect of ex	xercise on mu	scle endı	urance in p	oatients with C	CKD					
Study	Design	Stage of CKD	k (n)*	Exercise type	Mode	Outcome	SMD or MD (95% CI)	Effect size	P value	12	GRADE
Lu et a/ ³⁶	RCT	Dialysis	3 (193)	Mixed	Mixed	STS 10	MD: -4.69 (-9.01 to 0.38)	1	0.028	72.2%	0000
Bogataj <i>et al²⁵</i>	RCT	ЯH	5 (461)	Mixed	1	STS 10	SMD: -0.55 (-1.00 to 0.09)	Moderate	0.019	71.6%	⊕ 000
Lu <i>et al</i> ³⁶	RCT	Dialysis	6 (240)	Mixed	Mixed	STS 30	SMD: 0.43 (0.17 to 0.69)	Small	0.001	2.0%	$\Theta \oplus O O$
Zhang <i>et al⁵¹</i>	RCT	Я	5 (164)	RT	Intradialytic	STS 30	SMD: 0.42 (0.11,0.74)	Small	0.008	0.0%	⊕ ○○0
Sheng <i>et al</i> ⁴³	RCT	Я	3 (106)	Mixed	Intradialytic	STS 60	SMD: 0.71 (0.31,1.12)	Moderate	<0.001	0.0%	⊕ ○○0
Pei <i>et al</i> ⁴⁰	RCT/Quasi-RCT	Mixed	5 (445)	AE	1	STS 60	MD: 2.08 (1.1,3.05)	I	0.98	82.0%	⊕ ○○0
Nakamura <i>et al</i> ³⁸	RCT/Cross-over	Predialysis	3 (170)	Mixed	1	TUGT	SMD: -0.42 (-0.73 to 0.11)	Small	0.007	0.0%	000€
Heiwe <i>et al</i> ³³	RCT/Quasi-RCT	Mixed	7 (191)	Mixed	I	Walking capacity	SMD: -0.48 (-0.79 to 0.17)	Small	0.003	2.0%	⊕ 000
Heiwe and Jacobson ¹⁰	RCT	무	7 (174)	Mixed	Mixed	Walking capacity	SMD: -0.33 (-0.67,0.01)	Small	0.06	16.0%	⊖⊕⊕⊕
Mixed means aerobi *Number of included AE, aerobic exercise randomised controllk and go test.	c exercise combined studies and correspo ; CKD, chronic kidney od trial; RT, resistance	with resistance onding sample y disease; GRA e training; SMD,	training. size. DE, Gradir standardi	ng of Recom sed mean d	imendations As	ssessment, De 10, sit-to-star	svelopment and Evaluation; HD, ha id 10 test; STS 30, sit-to-stand 30	aemodialysis; ME test; STS 60, sit), mean diff -to-stand 60	erence; R(ЭТ, ăT, timed up

Table 5 Summary of th	ne effect of	exercise on body	compositio	n in patients with	CKD					
Study	Design	Stage of CKD	k (n)*	Exercise type	Mode	SMD (95% CI)	Effect size	P value	l ²	5
Chen <i>et al²⁷</i>	RCT	KTRs	4 (166)	Mixed	I	SMD: 0.02 (-0.28 to 0.33)	Small	0.89	0.0%	Ð
Yamamoto <i>et al⁴⁹</i>	RCT	Predialysis	10 (414)	AE	I	SMD: -0.19 (-0.38 to 0.00)	Small	0.026	0.0%	Ð
Zhang et al ⁵²	RCT	Predialysis	13 (466)	Mixed	I	SMD: -0.21 (-0.39 to 0.03)	Small	0.02	0.0%	Ð
Vanden Wyngaert et al ⁴⁷	RCT	Predialysis	9 (294)	AE	I	SMD: -0.36 (-0.60 to 0.13)	Small	0.002	48.0%	Ð
Mixed means aerobic exercise *Number of included studies an	combined with d correspondi	rresistance training. ing sample size.								

ADE

 $\bigcirc \oplus \oplus$

AE, aerobic exercise; CKD, chronic kidney disease; GRADE, Grading of Recommendations Assessment, Development and Evaluation; KTRs, kidney transplant recipients; RCT, randomised controlled trial; SMD, standardised mean difference.

Open access

studies) and a mean of 239 participants (ranging from 139 to 370) (table 6).

Fatigue was measured using the Rhoten Fatigue Scale, Visual Analogue Scale and Haemodialysis Patients Fatigue Scale. The effect of exercise on fatigue was investigated in two meta-analyses with a low heterogeneity (average $I^2=23.5\%$).^{45 53} The two meta-analyses revealed a statistically significant effect of exercise on fatigue. Although the meta-analyses reported large effect size, the quality of evidence was low⁴⁵ or very low⁵³ according to GRADE criteria.

Just one meta-analysis investigated the effects of exercise on restless legs syndrome in patients with CKD.⁴⁵ The results showed that pooled effect estimated for restless legs syndrome with statistically significant but considerable average heterogeneity ($l^2=87.0\%$). According to GRADE criteria, the overall evidence for this outcome was very low.

Dialysis adequacy

Dialysis adequacy was measured using the value of Kt/V. Six meta-analyses (reported in five articles) investigated the effects of exercise on Kt/V in patients with CKD with a mild heterogeneity (average $\hat{I}=25.7\%$).^{30 31 34 41 43} Comprehensive effect estimates from all the six metaanalyses with Kt/V outcomes showed that exercise had a beneficial effect. In three of the six meta-analyses, three reported a small effect size^{34 41 43} and one reported large effect size.³¹ According to GRADE criteria, all metaanalyses were rated as very low-quality evidence (table 6).

Health-related quality of life

Twenty-nine meta-analyses (reported in 13 articles) investigated the effect of exercise on HRQOL in patients with CKD.^{26 28 32 34 35 37 39-43 51 53} Among them, nine metaanalyses assessed the physical and mental subscale of the Short-Form Health Survey-36.^{28 32 34 37 41–43 51 53} Each metaanalysis included an average of 6 studies (ranging from 3 to 10) and 311 participants (ranging from 167 to 562). The included meta-analyses had moderate heterogeneity (average $l^2=51.0\%$) (table 7).

Of the 29 meta-analyses, a comprehensive effect estimate of the 28 meta-analyses shows that exercise is beneficial to the HRQOL of patients with CKD, but only 12 of 29 meta-analyses reported a statistically significant outcome.^{28 34 37 39 41-43 53} There were 13 of 29 meta-analyses reporting a small effect size,^{28 32 34 37 41 43 51 53} 4 were moderate^{32 37 39 41} and 6 were large.^{26 35 42} According to GRADE criteria, the overall of evidence for HRQOL was rated as very low (20 meta-analyses^{32 35 37 39–43 53}) \sim or low (9 meta-analyses^{26 28 34 41 51 53}).

Adverse events

Six meta-analyses reported exercise-related adverse events.26 28 38 41 43 44 Of the adverse effects, the most commonly reported were hypotension and cramping. Overall, the incidence of adverse events was approximately 0.3%.

Table 6 Sur	nmary of the effe	ct of exercis	e on dialysi	s-related s	ymptoms in pa	atients with C	KD				
Study	Design	Stage of CKD	k (n)*	Exercise type	Mode	Outcomes	SMD or MD (95% CI)	Effect size	P value	2	GRADE
Ferreira <i>et al</i> ⁶	RCT/Quasi- RCT	머	10 (346)	AE	Intradialytic	Kt//†	SMD: 2.21 (1.17 to 3.25)	Large	<0.001	92.0%	000⊕
Pu <i>et al</i> ⁴¹	RCT	ЯÐ	10 (301)	Mixed	Intradialytic	Kt/V	SMD: 0.29 (0.06 to 0.52)	Small	0.01	0.0%	000⊕
Huang <i>et al</i> ³⁴	RCT	ЯÐ	8 (257)	Mixed	Mixed	Kt/V	SMD: 0.19 (-0.06 to 0.43)	Small	0.14	0.0%	000⊕
Sheng <i>et al</i> ⁴³	RCT	ЯÐ	7 (233)	Mixed	Intradialytic	Kt/V	SMD: 0.27 (0.01 to 0.53)	Small	0.04	0.0%	000⊕
Ferrari <i>et al</i> ³⁰	RCT	ЯÐ	12 (370)	AE	Intradialytic	Kt/V	MD: 0.08 (0.0 to 0.15)	I	0.04	56.0%	000⊕
Ferrari <i>et al</i> ³¹	RCT	ЧD	6 (220)	RT	Intradialytic	Kt/V	MD: 0.10 (0.0 to 0.2)	I	0.06	6.0%	0 00 ⊕
Song <i>et al</i> ⁴⁵	RCT	ЯÐ	4 (141)	Mixed	Mixed	RLS	SMD: -1.79 (-2.21 to 1.37)	Large	<0.001	87.0%	000⊕
Song <i>et al</i> ⁴⁵	RCT	ЯÐ	3 (139)	Mixed	Mixed	Fatigue	SMD: -0.85 (-1.20 to 0.50)	Large	<0.001	0.0%	000⊕
Zhao <i>et al⁵³</i>	RCT	Dialysis	3 (141)	Mixed	I	Fatigue	SMD: -0.97 (-1.32 to 0.62)	Large	<0.001	47.0%	$\bigcirc \bigcirc \oplus \oplus \bigcirc$
Mixed means (*Number of inc	aerobic exercise cor luded studies and c	mbined with r corresponding	esistance tra 3 sample size	ining.							

AE, aerobic exercise; CKD, chronic kidney disease; GRADE, Grading of Recommendations Assessment, Development and Evaluation; HD, haemodialysis; KTRs, kidney transplant recipients; MD, mean difference; RCT, randomised controlled trial; RLS, restlesslegs syndrome; RT, resistance training; SMD, standardised mean difference. dicator to assess

Open access

DISCUSSION Summary of main results

Several meta-analyses have been published on exercise interventions in patients with CKD.⁵⁵ The findings of these meta-analyses should be assessed to determine if the evidence is consistent among the studies. This umbrella review included 31 eligible articles involving 120 separate meta-analyses investigating the effect of exercise on the health outcomes in patients with CKD. There was low-quality or very low-quality evidence for moderate beneficial effects of exercise on cardiorespiratory fitness, muscle strength and body composition. In addition, there was very low-quality evidence for minor beneficial effects of exercise on muscle endurance, cardiovascular risk factors, dialysis-related symptoms and HRQOL. Few adverse events related to exercise indicate that exercise is safe for patients with CKD.

Interpretation of study effects

Cardiovascular disease is a frequent complication of CKD and is the leading cause of death in patients with CKD.⁵⁶ Hypertension is an important modifiable risk factor for cardiovascular diseases and progressive renal dysfunction in patients with CKD.⁵⁷ The present overview showed that exercise has a small to moderate effect on blood pressure (SMD: -0.75 to 0.04 for systolic blood pressure and SMD: -0.47 to 0.04 for diastolic blood pressure); it is an appealing strategy for blood pressure control in patients with CKD. However, the dose effects of exercise in the context of the cardiovascular health of patients with CKD should be considered. A recent cohort study found that 7.5-15 metabolic equivalent hours per week (MET-h/week) was associated with the lowest risk of cardiovascular events.⁵⁸ Regrettably, the benefit of exercise on cardiovascular risk factors cannot be determined because there are an insufficient number of conclusive studies that assess exercise effects on overall cardiovascular health. In a systematic review by Heiwe et al, a meta-analysis including two trials found that exercise improved cardiovascular function in patients with CKD, as reflected in the SD of all normal RR intervals and left ventricular mass index.¹⁰ Furthermore, a recent randomised controlled trial published by Graham-Brown et al indicated that intradialytic exercise could reduce left ventricular mass and is safe, deliverable and well-tolerated.⁵⁹ Although the GRADE evidence was low, exercise should be recommended for patients with CKD, particularly those comorbid with cardiovascular disease. Future randomised controlled exercise trials need to focus more on the role of exercise in cardiovascular events in patients with CKD.

Physical fitness is necessary for participation in activities of daily living. The exercise provided the best results in improving cardiorespiratory fitness and muscle strength in patients with CKD, with more than half of the metaanalyses reporting moderate or large effect sizes, regardless of the quality of evidence. Cardiorespiratory fitness is considered a significant independent predictor of mortality, and muscle strength is an essential indicator

		Stane of		Evarcica				Effort			
Study	Design	CKD	k (n)*	type	Mode	Outcomes	SMD or MD (95% CI)	size	P value	β2	GRADE
Salhab <i>et al</i> ⁴²	RCT	ЧD	5 (282)	AE	Intradialytic	PCS	SMD: 1.82 (-0.92 to 4.55)	Large	0.19	98.0%	0 00 ⊕
Chung <i>et al</i> ²⁸	RCT	ЯΗ	6 (229)	Mixed	Intradialytic	PCS	SMD: 0.46 (0.20 to 0.73)	Small	<0.001	1.90%	$\bigcirc \bigcirc \textcircled{0} \textcircled{0} \textcircled{0} \textcircled{0}$
Zhang <i>et al</i> ⁵¹	RCT	ЯΗ	7 (297)	RT	Intradialytic	PCS	SMD: 0.23 (-0.00 to 0.46)	Small	0.055	0.0%	$\bigcirc \bigcirc \textcircled{0} \textcircled{0} \textcircled{0} \textcircled{0} \textcircled{0}$
Pu <i>et al</i> ⁴¹	RCT	ЯΗ	10 (320)	Mixed	Intradialytic	PCS	SMD: 0.57 (0.14 to 1.01)	Moderate	0.01	70.0%	000 ⊕
Zhao <i>et al⁵³</i>	RCT	Dialysis	5 (186)	Mixed	I	PCS	SMD: 0.31 (0.02 to 0.61)	Small	0.04	46.0%	$\bigcirc \bigcirc \textcircled{0} \textcircled{0} \textcircled{0} \textcircled{0} \textcircled{0}$
Huang <i>et al</i> ³⁴	RCT	ДH	7 (263)	Mixed	Mixed	PCS	SMD: 0.34 (0.09 to 0.59)	Small	0.007	27.0%	$\bigcirc \bigcirc \textcircled{0} \textcircled{0} \textcircled{0} \textcircled{0} \textcircled{0}$
Matsuzawa <i>et al</i>	RCT	ДH	9 (264)	Mixed	Mixed	PCS	SMD: 0.53 (0.52 to 0.82)	Moderate	<0.001	19.0%	000⊕
Sheng <i>et al</i> ⁴³	RCT	ДH	7 (256)	Mixed	Intradialytic	PCS	SMD: 0.30 (0.05 to 0.55)	Small	0.02	39.5%	000⊕
Neto <i>et al</i> ³²	RCT	QН	7 (187)	Mixed	Intradialytic	PCS	SMD: 0.50 (-0.19 to 1.18)	Moderate	0.16	62.0%	000 ⊕
Salhab <i>et al⁴²</i>	RCT	ДH	5 (282)	AE	Intradialytic	MCS	SMD: 1.02 (0.31 to 1.73)	Large	0.005	75.0%	000⊕
Chung <i>et al</i> ²⁸	RCT	ЯΗ	5 (193)	Mixed	Intradialytic	MCS	SMD: 0.23 (-0.05 to 0.52)	Small	0.109	0.0%	$\bigcirc \bigcirc \textcircled{0} \textcircled{0} \textcircled{0} \textcircled{0}$
Zhang <i>et al</i> ⁵¹	RCT	ЯΗ	7 (297)	RT	Intradialytic	MCS	SMD: 0.13 (-0.10 to 0.36)	Small	0.082	46.5%	$\bigcirc \bigcirc \textcircled{0} \textcircled{0} \textcircled{0} \textcircled{0}$
Pu <i>et al</i> ⁴¹	RCT	QН	8 (219)	Mixed	Intradialytic	MCS	SMD: 0.19 (-0.09 to 0.46)	Small	0.18	30.0%	$\bigcirc \bigcirc \textcircled{0} \textcircled{0} \textcircled{0} \textcircled{0}$
Zhao <i>et al⁵³</i>	RCT	Dialysis	5 (186)	Mixed	I	MCS	SMD: 0.30 (-0.20 to 0.80)	Small	0.24	64.0%	000 ⊕
Huang et a/ ³⁴	RCT	ЧD	7 (263)	Mixed	Mixed	MCS	SMD: 0.27 (0.02 to 0.51)	Small	0.03	0.0%	$\bigcirc \bigcirc \oplus \oplus \bigcirc$
Matsuzawa <i>et al</i>	7 RCT	ЯΗ	8 (228)	Mixed	Mixed	MCS	SMD: 0.14 (-0.15 to 0.42)	Small	0.34	10.0%	000 ⊕
Sheng <i>et al</i> ⁴³	RCT	НD	5 (167)	Mixed	Intradialytic	MCS	SMD: 0.14 (-0.16 to 0.43)	Small	0.37	14.8%	$\oplus \bigcirc \bigcirc \bigcirc \bigcirc \\$
Neto <i>et al</i> ³²	RCT	ЯΗ	7 (185)	Mixed	Intradialytic	MCS	SMD: 0.39 (-0.19 to 0.98)	Small	0.19	50.0%	000 ⊕
Pei <i>et al</i> ⁴⁰	RCT/Quasi- RCT	Mixed	6 (522)	AE	I	Physical function (SF-36)	MD: 8.36 (-1.24 to 17.95)	I	0.09	76.0%	⊕ ○○○
Pei <i>et al</i> ⁴⁰	RCT/Quasi- RCT	Mixed	7 (562)	AE	I	Physical role (SF- 36)	MD: 14.65 (1.47 to 27.84)	I	0.03	78.0%	⊕ ○○
Pei <i>et al</i> ⁴⁰	RCT/Quasi- RCT	Mixed	6 (447)	AE	I	Social function (SF-36)	MD: 8.24 (-1.09 to 17.58)	I	0.08	85.0%	⊕ ○○○
Pei <i>et al</i> ⁴⁰	RCT/Quasi- RCT	Mixed	6 (513)	AE	1	Pain (SF-36)	MD: 5.94 (1.65 to 10.23)	I	0.007	49.0%	⊕ ○○
Pei <i>et al</i> ⁴⁰	RCT/Quasi- RCT	Mixed	7 (562)	AE	I	General health (SF- 36)	MD: 8.90 (2.48 to 15.32)	I	0.007	71.0%	0 00 ⊕
Pei <i>et al</i> ⁴⁰	RCT/Quasi- RCT	Mixed	6 (542)	AE	I	Mental health (SF- 36)	MD: 7.30 (-0.94 to 15.54)	I	0.08	84.0%	⊕ ○○
Cheema <i>et al</i> ²⁶	RCT	Predialysis	6 (223)	RT	I	HRQOL	SMD: 0.83 (0.51 to 1.16)	Large	0.226	27.8%	$\bigcirc \bigcirc \oplus \oplus \bigcirc \bigcirc$
Oguchi <i>et al</i> ³⁹	RCT	KTRs	4 (179)	Mixed	I	HRQOL	SMD: 0.54 (0.02 to 1.07)	Moderate	0.04	58.0%	000
											Continued

Table 7 Continu	ed										
Study	Design	Stage of CKD	k (n)*	Exercise type	Mode	Outcomes	SMD or MD (95% CI)	Effect size	P value	12	GRADE
Ju et a/ ³⁵	RCT	Mixed	3 (387)	Mixed	I	Symptom/Problem (KDQOL)	SMD: 1.92 (-1.06 to 4.90)	Large	0.21	99.0%	000€
Ju et al ³⁵	RCT	Mixed	3 (387)	Mixed	I	Effects of kidney disease (KDQOL)	SMD: -3.69 (-8.56 to 1.19)	Large	0.14	99.0%	000 ⊕
Ju et al ³⁵	RCT	Mixed	3 (387)	Mixed	I	Burden of kidney disease (KDQOL)	SMD: 1.04 (-0.75 to 2.82)	Large	0.26	98.0%	000€
Mixed means aerob *Number of includer AE, aerobic exercise related quality of life RCT, randomised co	ic exercise corr d studies and co s; CKD, chronic ; KDQOL, kidne introlled trial; R	nbined with resourcesponding : kidney diseas y disease que T, resistance tr	sistance trai sample size se; COM, cc ality of life; H raining; SF-	ning. mbine; GF XTRs, kidn 36, ShortF	(ADE, Grading o y transplant rec orm Health Sun	f Recommendations As: sipients; MCS, mental c rey-36; SMD, standardi	sessment, Development and Evalu omponent summary, MD, mean di sed mean difference.	lation; HD, ha fference; PCS	temodialysis 3, physical o	; HRQOL, ŀ omponent	iealth- summary;

Ć

of physical performance in patients with CKD.⁶⁰ It is well known that aerobic exercise is the 'gold standard' for cardiorespiratory rehabilitation⁶¹ and resistance training for muscle strength improvement.⁶² However, a combination of aerobic and resistance exercises may have a more profound effect on patients with CKD based on the current review. Meta-analyses by Andrade *et al* showed that combined training benefits cardiorespiratory fitness in patients with CKD.²⁴

Both sarcopenia and obesity have increased mortality risk and progression to end-stage renal disease in patients with CKD.⁶³ Unlike patients receiving dialysis, treatment requirements for patients with predialysis CKD are based on maintaining a 'healthy weight' and preventing or attenuating obesity.¹⁴ In this overview, the effectiveness of exercise for body mass index was supported by four analyses with small effect sizes and moderate quality of evidence. Based on the results, exercise may contribute to lower body mass index in patients with CKD. However, additional studies are needed to confirm the benefits of exercise programmes for reducing sarcopenia and weight.

CKD population experience multiple symptoms that affect the patient's prognosis and HRQOL.⁶⁴ Patients who received dialysis treatment commonly reported restless legs syndrome, fatigue and inadequate dialysis due to kidney function deterioration and dialysis-related side effects.⁶⁵⁶⁶ These symptoms affect sleep and daily activities and impose considerable psychological distress and economic burden.⁶⁷ An increasing number of researchers have investigated the role of exercise as an important non-pharmacological strategy for preventing and/or treating symptoms.⁶⁸⁶⁹ The results of a small number of meta-analyses suggested the beneficial effect of exercise on dialysis adequacy (SMD: 0.19 to 2.21) and improving restless legs syndrome (SMD: -1.79) and fatigue symptoms (SMD: -0.97 to -0.85). Nevertheless, the efficacy of exercise in patients with CKD for preventing dialysisrelated symptoms awaits new clinical evidence.

With similar results obtained in another overview that included chronic disease,⁷⁰ results from this overview demonstrated minor beneficial effects of exercise on HRQOL, irrespective of the evidence level in patients with CKD. Improved HRQOL is vital because most of the population reported poor health and well-being due to diet restriction, weakness and dialysis treatment.⁷¹ The consistent health benefits of exercise in this overview demonstrated that exercise could be a strategy to improve the poor long-term prognosis in patients with CKD.

Several meta-analyses reported exercise-related adverse events. Based on the reported adverse events, we calculate that only three adverse events occurred per 1000 patients with CKD. The low incidence of adverse events indicated that the benefits of exercise in patients with CKD outweigh its potential risks and most reflected typical response to exercise (eg, muscle soreness). However, most meta-analyses only included intradialytic exercise for haemodialysis patients in their assessments. Exercises during haemodialysis are usually performed under the supervision of a healthcare worker to ensure safety.⁷² It has been reported that all patients with CKD are at risk for cardiovascular events (eg, arrhythmias, myocardial ischaemia) during exercise. Therefore, medical screening should be performed before exercise to determine which patients may be at increased risk for cardiovascular accidents.⁷³ In addition, special attention should be paid to dry weight and blood pressure in patients with haemodialysis-dependent CKD to avoid excessive volume loading or dehydration, which may increase the risk associated with exercise.⁶⁰

Implications for clinical

Taken together, there is good reason to recommend exercise for improving prognosis in patients with CKD. Evidence from most randomised controlled trials increased confidence in the findings of this umbrella review. Because most of the meta-analyses assessed in this study did not detail the exercises instituted, it is difficult to make recommendations about the type of exercise that would be the most beneficial for patients with CKD. Although exercise's effect sizes on improving health prognosis of patients with CKD were generally moderate, these effects may bring some clinical benefit to patients experiencing impaired function or symptom distress. Despite numerous meta-analyses providing only low-quality or very low-quality evidence, similar beneficial effects of exercise were reported by meta-analyses of randomised controlled trials with different grades of evidence. Remarkably, a recently published trial found that a 6-month intradialytic exercise programme effectively reduces healthcare costs.⁷⁴ Overall, exercise should be integrated into the care of CKD, but the overall benefit of exercise to CKD is still debatable.

Limitations

This overview has several limitations. First, most metaanalyses included in this review involve haemodialysis patients, limiting the results' extrapolation to other CKD stages. Second, improvement of flexibility in patients with CKD was not investigated. Flexibility is an important component of physical fitness that impacts muscular injury.⁷⁵ The evidence for the efficacy of exercise on flexibility improvement is insufficient for a systematic review or meta-analysis. Third, since the search strategy was limited to English, this review may have language bias. It is unknown whether meta-analyses published in other languages would affect the results of our study. Fourth, the results may have been influenced by an overlap in the original studies. Fifth, the accuracy of the MD data cannot be guaranteed. Sixth, subgroup analyses of different types of exercise were not performed as described in the published protocol because most of the included metaanalyses did not detail the exercises. Seventh, both body composition and cardiovascular risk factors are common terms. However, the inclusion of studies was limited, so this review focused only on body mass index and blood

pressure, and more evidence is still needed for the effects
 of other assessment metrics.

CONCLUSION

In patients with CKD, exercise improves muscle strength, endurance, body composition and HRQOL. At the same time, exercise decreases blood pressure and dialysisrelated symptoms in patients with CKD. However, the quality of the evidence was considered low or very low for all outcomes indicating that we have low certainty evidence to support the findings above. More rigorous study is still needed in the future. Nevertheless, given the health benefits of physical activity, exercise should be integrated into renal care for a patient with any stage of CKD.

Contributors FZ and LH conceived and designed the review. YB and XZ searched databases, extracted the data and conducted the statistical analysis. WZ revised the manuscript. WW and HZ provided technical support. All authors had read and approved the final manuscript and agreed on its submission. FZ was the guarantor of this work.

Funding This study was supported by Longhua Hospital Shanghai University of Traditional Chinese Medicine (grant number: Y21026), and Longhua Hospital Shanghai University of Traditional Chinese Medicine (YW.006.035)

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD

Huachun Zhang http://orcid.org/0000-0002-7400-0869

REFERENCES

- 1 Zoccali C, Vanholder R, Massy ZA, et al. The systemic nature of CKD. Nat Rev Nephrol 2017;13:344–58.
- 2 GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the global burden of disease study 2017. *Lancet* 2020;395:709–33.
- 3 Yang C, Gao B, Zhao X, et al. Executive summary for China kidney disease network (CK-NET) 2016 annual data report. *Kidney Int* 2020;98:1419–23.

Open access

- 4 Cheng H-T, Xu X, Lim PS, et al. Worldwide epidemiology of diabetes-related end-stage renal disease, 2000-2015. *Diabetes Care* 2021;44:89-97.
- 5 Roshanravan B, Robinson-Cohen C, Patel KV, *et al.* Association between physical performance and all-cause mortality in CKD. *J Am Soc Nephrol* 2013;24:822–30.
- 6 Wang XH, Mitch WE. Mechanisms of muscle wasting in chronic kidney disease. *Nat Rev Nephrol* 2014;10:504–16.
- 7 Hoshino J. Renal rehabilitation: exercise intervention and nutritional support in dialysis patients. *Nutrients* 2021;13:1444.
- 8 Wilund KR, Viana JL, Perez LM. A critical review of exercise training in hemodialysis patients: personalized activity prescriptions are needed. *Exerc Sport Sci Rev* 2020;48:28–39.
- 9 Tentori F, Elder SJ, Thumma J, *et al.* Physical exercise among participants in the dialysis outcomes and practice patterns study (DOPPS): correlates and associated outcomes. *Nephrol Dial Transplant* 2010;25:3050–62.
- 10 Heiwe S, Jacobson SH. Exercise training in adults with CKD: a systematic review and meta-analysis. *Am J Kidney Dis* 2014;64:383–93.
- 11 Wong L, Duque G, McMahon LP. Sarcopenia and frailty: challenges in mainstream nephrology practice. *Kidney Int Rep* 2021;6:2554–64.
- 12 Rampersad C, Darcel J, Harasemiw O, et al. Change in physical activity and function in patients with baseline advanced Nondialysis CKD. Clin J Am Soc Nephrol 2021;16:1805–12.
- 13 March DS, Graham-Brown MP, Young HM, et al. 'There is nothing more deceptive than an obvious fact': more evidence for the prescription of exercise during haemodialysis (intradialytic exercise) is still required. Br J Sports Med 2017;51:1379.
- 14 Clinical Practice Guideline. Exercise and lifestyle in chronic kidney disease. Available: https://renal.org/sites/renal.org/files/Exercise% 20and%20Lifestyle%20in%20CKD%20clinical%20practice% 20guideline33_v4_FINAL_0.pdf
- 15 Yamagata K, Hoshino J, Sugiyama H, et al. Clinical practice guideline for renal rehabilitation: systematic reviews and recommendations of exercise therapies in patients with kidney diseases. *Renal Replacement Therapy* 2019;5.
- 16 Deschamps T. Let's programme exercise during haemodialysis (intradialytic exercise) into the care plan for patients, regardless of age. *Br J Sports Med* 2016;50:1357–8.
- 17 Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;350:g7647.
- 18 Zhang F, Wang H, Huang L, et al. Therapeutic effects of exercise interventions for patients with chronic kidney disease: protocol for an overview of systematic reviews and meta-analyses of clinical trials. BMJ Open 2021;11:e043011.
- 19 Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or nonrandomised studies of healthcare interventions, or both. BMJ 2017;358:j4008.
- 20 Grgic J, Grgic I, Pickering C, et al. Wake up and smell the coffee: caffeine supplementation and exercise performance-an umbrella review of 21 published meta-analyses. Br J Sports Med 2020;54:681–8.
- 21 Cohen J. Quantitative methods in psychology: a power primer. *Psychological Bulletin* 1992;112:115–59.
- 22 Higgins JPT, Thompson SG, Deeks JJ, *et al*. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557–60.
- 23 Atkins D, Best D, Briss PA, *et al*. Grading quality of evidence and strength of recommendations. *BMJ* 2004;328:1490.
- 24 Andrade FP, Rezende PdeS, Ferreira TdeS, et al. Effects of intradialytic exercise on cardiopulmonary capacity in chronic kidney disease: systematic review and meta-analysis of randomized clinical trials. Sci Rep 2019;9:18470.
- 25 Bogataj Š, Pajek M, Pajek J, et al. Exercise-Based interventions in hemodialysis patients: a systematic review with a meta-analysis of randomized controlled trials. J Clin Med 2019;9. doi:10.3390/ jcm9010043
- 26 Cheema BS, Chan D, Fahey P, *et al*. Effect of progressive resistance training on measures of skeletal muscle hypertrophy, muscular strength and health-related quality of life in patients with chronic kidney disease: a systematic review and meta-analysis. *Sports Med* 2014;44:1125–38.
- 27 Chen G, Gao L, Li X. Effects of exercise training on cardiovascular risk factors in kidney transplant recipients: a systematic review and meta-analysis. *Ren Fail* 2019;41:408–18.
- 28 Chung Y-C, Yeh M-L, Liu Y-M. Effects of intradialytic exercise on the physical function, depression and quality of life for haemodialysis patients: a systematic review and meta-analysis of randomised controlled trials. *J Clin Nurs* 2017;26:1801–13.

- 29 Clarkson MJ, Bennett PN, Fraser SF, et al. Exercise interventions for improving objective physical function in patients with end-stage kidney disease on dialysis: a systematic review and meta-analysis. Am J Physiol Renal Physiol 2019;316:F856–72.
- 30 Ferrari F, Helal L, Dipp T, *et al.* Intradialytic training in patients with end-stage renal disease: a systematic review and meta-analysis of randomized clinical trials assessing the effects of five different training interventions. *J Nephrol* 2020;33:251–66.
- 31 Ferreira GD, Bohlke M, Correa CM, *et al.* Does Intradialytic exercise improve removal of solutes by hemodialysis? A systematic review and meta-analysis. *Arch Phys Med Rehabil* 2019;100:2371–80.
- 32 Gomes Neto M, de Lacerda FFR, Lopes AA, *et al.* Intradialytic exercise training modalities on physical functioning and health-related quality of life in patients undergoing maintenance hemodialysis: systematic review and meta-analysis. *Clin Rehabil* 2018;32:1189–202.
- 33 Heiwe S, Jacobson SH, Jacobson SH. Exercise training for adults with chronic kidney disease. *Cochrane Database Syst Rev* 2011;10:Cd003236.
- 34 Huang M, Lv A, Wang J, et al. Exercise training and outcomes in hemodialysis patients: systematic review and meta-analysis. Am J Nephrol 2019;50:240–54.
- 35 Ju H, Chen H, Mi C, *et al.* The impact of home-based exercise program on physical function of chronic kidney disease patients: a meta-analysis of randomized controlled trials. *Physikalische Medizin, Rehabilitationsmedizin, Kurortmedizin* 2020;30:108–14.
- 36 Lu Y, Wang Y, Lu Q. Effects of exercise on muscle fitness in dialysis patients: a systematic review and meta-analysis. *Am J Nephrol* 2019;50:291–302.
- 37 Matsuzawa R, Hoshi K, Yoneki K, et al. Exercise training in elderly people undergoing hemodialysis: a systematic review and metaanalysis. *Kidney Int Rep* 2017;2:1096–110.
- 38 Nakamura K, Sasaki T, Yamamoto S, et al. Effects of exercise on kidney and physical function in patients with non-dialysis chronic kidney disease: a systematic review and meta-analysis. *Sci Rep* 2020;10:18195.
- 39 Oguchi H, Tsujita M, Yazawa M, et al. The efficacy of exercise training in kidney transplant recipients: a meta-analysis and systematic review. *Clin Exp Nephrol* 2019;23:275–84.
- 40 Pei G, Tang Y, Tan L, et al. Aerobic exercise in adults with chronic kidney disease (CKD): a meta-analysis. Int Urol Nephrol 2019;51:1787–95.
- 41 Pu J, Jiang Z, Wu W, et al. Efficacy and safety of intradialytic exercise in haemodialysis patients: a systematic review and meta-analysis. BMJ Open 2019;9:e020633.
- 42 Salhab N, Karavetian M, Kooman J, et al. Effects of intradialytic aerobic exercise on hemodialysis patients: a systematic review and meta-analysis. J Nephrol 2019;32:549–66.
- 43 Sheng K, Zhang P, Chen L, *et al.* Intradialytic exercise in hemodialysis patients: a systematic review and meta-analysis. *Am J Nephrol* 2014;40:478–90.
- 44 Smart N, Steele M, Steele M. Exercise training in haemodialysis patients: a systematic review and meta-analysis. *Nephrology* 2011;16:626–32.
- 45 Song Y-Y, Hu R-J, Diao Y-S, et al. Effects of exercise training on restless legs syndrome, depression, sleep quality, and fatigue among hemodialysis patients: a systematic review and meta-analysis. J Pain Symptom Manage 2018;55:1184–95.
- 46 Thompson S, Wiebe N, Padwal RS, *et al.* The effect of exercise on blood pressure in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. *PLoS One* 2019;14:e0211032.
- 47 Vanden Wyngaert K, Van Craenenbroeck AH, Van Biesen W, et al. The effects of aerobic exercise on eGFR, blood pressure and VO2peak in patients with chronic kidney disease stages 3-4: a systematic review and meta-analysis. PLoS One 2018;13:e0203662.
- 48 Wu X, Yang L, Wang Y, et al. Effects of combined aerobic and resistance exercise on renal function in adult patients with chronic kidney disease: a systematic review and meta-analysis. *Clin Rehabil* 2020;34:851–65.
- 49 Yamamoto R, Ito T, Nagasawa Y, et al. Efficacy of aerobic exercise on the cardiometabolic and renal outcomes in patients with chronic kidney disease: a systematic review of randomized controlled trials. J Nephrol 2021;34:155–64.
- 50 Yang H, Wu X, Wang M. Exercise affects cardiopulmonary function in patients with chronic kidney disease: a meta-analysis. *Biomed Res Int* 2017;2017:1–9.
- 51 Zhang F, Zhou W, Sun Q, et al. Effects of intradialytic resistance exercises on physical performance, nutrient intake and quality of life among haemodialysis people: a systematic review and metaanalysis. *Nurs Open* 2021;8:529–38.

- 52 Zhang L, Wang Y, Xiong L, *et al.* Exercise therapy improves eGFR, and reduces blood pressure and BMI in non-dialysis CKD patients: evidence from a meta-analysis. *BMC Nephrol* 2019;20:398.
- 53 Zhao Q-G, Zhang H-R, Wen X, et al. Exercise interventions on patients with end-stage renal disease: a systematic review. Clin Rehabil 2019;33:147–56.
- 54 Invalid citation
- 55 Clyne N, Anding-Rost K. Exercise training in chronic kidney diseaseeffects, expectations and adherence. *Clin Kidney J* 2021;14:ii3–14.
- 56 Webster AC, Nagler EV, Morton RL, *et al.* Chronic kidney disease. Lancet 2017;389:1238–52.
- 57 Cheung AK, Chang TI, Cushman WC, et al. Blood pressure in chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. *Kidney Int* 2019;95:1027–36.
- 58 Kuo CP, Tsai MT, Lee KH, et al. Dose-Response effects of physical activity on all-cause mortality and major cardiorenal outcomes in chronic kidney disease. Eur J Prev Cardiol 2021.
- 59 Graham-Brown MPM, March DS, Young R, *et al.* A randomized controlled trial to investigate the effects of intra-dialytic cycling on left ventricular mass. *Kidney Int* 2021;99:1478–86.
- 60 Zelle DM, Klaassen G, van Adrichem E, *et al.* Physical inactivity: a risk factor and target for intervention in renal care. *Nat Rev Nephrol* 2017;13:152–68.
- 61 Mezzani A, Hamm LF, Jones AM, et al. Aerobic exercise intensity assessment and prescription in cardiac rehabilitation: a joint position statement of the European association for cardiovascular prevention and rehabilitation, the American association of cardiovascular and pulmonary rehabilitation and the Canadian association of cardiac rehabilitation. *Eur J Prev Cardiol* 2013;20:442–67.
- 62 Chan D, Cheema BS. Progressive resistance training in end-stage renal disease: systematic review. *Am J Nephrol* 2016;44:32–45.
- 63 Androga L, Sharma D, Amodu A, *et al.* Sarcopenia, obesity, and mortality in US adults with and without chronic kidney disease. *Kidney Int Rep* 2017;2:201–11.

- 64 Weisbord SD, Fried LF, Arnold RM, et al. Prevalence, severity, and importance of physical and emotional symptoms in chronic hemodialysis patients. J Am Soc Nephrol 2005;16:2487–94.
- 65 Flythe JE, Hilliard T, Castillo G, et al. Symptom prioritization among adults receiving In-Center hemodialysis: a mixed methods study. *Clin J Am Soc Nephrol* 2018;13:735–45.
- 66 Gregg LP, Bossola M, Ostrosky-Frid M, *et al.* Fatigue in CKD: epidemiology, pathophysiology, and treatment. *Clin J Am Soc Nephrol* 2021;16:1445-1455.
- 67 Flythe JE, Dorough A, Narendra JH, *et al.* Perspectives on symptom experiences and symptom reporting among individuals on hemodialysis. *Nephrol Dial Transplant* 2018;33:1842–52.
- 68 Metzger M, Abdel-Rahman EM, Boykin H, et al. A narrative review of management strategies for common symptoms in advanced CKD. *Kidney Int Rep* 2021;6:894–904.
- 69 Johansen KL. The promise and challenge of aerobic exercise in people undergoing long-term hemodialysis. *Clin J Am Soc Nephrol* 2021;16:505–7.
- 70 Fuller JT, Hartland MC, Maloney LT, et al. Therapeutic effects of aerobic and resistance exercises for cancer survivors: a systematic review of meta-analyses of clinical trials. Br J Sports Med 2018;52:1311.
- 71 Amir N, Tong A, McCarthy H, et al. Trajectories of quality of life in chronic kidney disease: a novel perspective of disease progression. *Nephrol Dial Transplant* 2021;36:1563–5.
- 72 Parker K. Intradialytic exercise is medicine for hemodialysis patients. *Curr Sports Med Rep* 2016;15:269–75.
- 73 Smart NA, Williams AD, Levinger I, et al. Exercise & Sports Science Australia (ESSA) position statement on exercise and chronic kidney disease. J Sci Med Sport 2013;16:406–11.
- 74 March DS, Hurt AW, Grantham CE, et al. A cost-effective analysis of the CYCLE-HD randomized controlled trial. *Kidney Int Rep* 2021;6:1548–57.
- 75 Fuhrmann I, Krause R. Principles of exercising in patients with chronic kidney disease, on dialysis and for kidney transplant recipients. *Clin Nephrol* 2004;61 Suppl 1:S14–25.